For the Inventor, By the Inventor

Enter assignee name

Cheongju-si, South Korea

Medytox Inc.

USPTO Granted Patents = 21

EPO Patents = 10

Trademarks = 5

Forward Citations = 125

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Gi Hyeok Yang (17 out of 17 patents)

Hyun Ho Jung (17 out of 27 patents)

Chang Hoon Rhee (14 out of 14 patents)

4. Hack Woo Kim (7 out of 7 patents)

5. Hyun Jee Kim (6 out of 6 patents)

6. Hee Dong Woo (4 out of 5 patents)

7. Junho Lee (3 out of 95 patents)

8. Sujin Cho (2 out of 2 patents)

9. Sung Bum Kim (2 out of 2 patents)

10. Seung Hwan Baek (2 out of 2 patents)

11. Hyun Uk Jeong (2 out of 4 patents)

12. Gi Hyuck Ryu (1 out of 1 patent)

13. Hyung Pyo Hong (1 out of 1 patent)

14. Jung Hyun Song (1 out of 1 patent)

15. Joon Chan Kong (1 out of 1 patent)

21 patents: Sort by Forward Citations

1. 12419836 - Extracellular vesicles derived from recombinant microorganism including polynucleotide encoding target protein and use thereof (2025-09-23),

2. 12377137 - Long lasting effect of new botulinum toxin formulations (2025-08-05),

3. 12274739 - Pharmaceutical liquid composition of botulinum toxin with improved stability (2025-04-14),

4. 11957741 - Long lasting effect of new botulinum toxin formulations (2024-04-16),

5. 11801276 - Microorganism having ability to degrade ethanol and acetaldehyde, and composition and kit each including the same (2023-10-31),

6. 11596673 - Long lasting effect of new botulinum toxin formulations (2023-03-07),

7. 11590212 - Long lasting effect of new botulinum toxin formulations (2023-02-28),

8. 11517576 - Methods and compositions of bile acids and salts for reduction of fat (2022-12-06),

9. 11331598 - Method of isolating botulinum toxin from botulinum toxin-containing solution (2022-05-17),

10. 11198859 - Recombinant polynucleotide coding for polypeptide comprising reporter moiety, substrate moiety and destabilizing moiety, host cell comprising same and use of same (2021-12-14),

11. 11161872 - Methods for preparing bile acids (2021-11-02),

12. 10729700 - Methods and compositions of bile acids and salts for reduction of fat (2020-08-04),

13. 10293034 - Pharmaceutical liquid composition of botulinum toxin with improved stability and method of use (2019-05-21),

14. 10143728 - Long lasting effect of new botulinum toxin formulations (2018-12-04),

15. 10105387 - Temperature sensitive adhesion prevention composition and use thereof (2018-10-23),

MEDYTOX INC. is a biopharmaceutical company that specializes in the development and commercialization of botulinum toxin and dermal filler products. With a mission to improve people's health and well-being, the company focuses on innovative solutions in the field of medical aesthetics. MEDYTOX has a strong portfolio of licensed and approved products and continues to conduct research to provide safe and effective treatments. For more information, visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#7 in Cheongju-si

#595 in South Korea

#29,080 in the World

Cheongju-si, South Korea

Medytox Inc.

Forward Citations = 125

40 inventors:

Gi Hyeok Yang (17 out of 17 patents)

Hyun Ho Jung (17 out of 27 patents)

Chang Hoon Rhee (14 out of 14 patents)

4. Hack Woo Kim (7 out of 7 patents)

5. Hyun Jee Kim (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…